

BIOSPECIFICS TECHNOLOGIES CORP  
Form 8-K  
November 21, 2014

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, DC 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **November 21, 2014**

**BIOSPECIFICS TECHNOLOGIES CORP.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-34236**  
(Commission  
File Number)

**11-3054851**  
(IRS Employer  
Identification No.)

**35 Wilbur Street**  
**Lynbrook, NY**  
(Address of principal executive offices)

**11563**  
(Zip Code)

Registrant's telephone number, including area code: **516.593.7000**

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

## Introductory Comment

Throughout this Current Report on Form 8-K, the terms we, us, our and Company refer to BioSpecifics Technologies Corp.

## Item 8.01 Other Events

On November 21, 2014, the Company announced new data on XIAFLEX for the treatment of Peyronie's disease from the Phase 2 and the pivotal Phase 3 IMPRESS (The **I**nvestigation for **M**aximal **P**eyronie's **R**eduction **E**fficacy and **S**afety **S**tudies) trials, presented by BioSpecifics' licensee, Auxilium Pharmaceuticals, Inc. at the 20<sup>th</sup> Annual Fall Scientific Meeting of the Sexual Medicine Society of North America held in Miami, FL from November 20-23, 2014.

A press release regarding the announcement is attached hereto as Exhibit 99.1.

## Item 9.01 Financial Statements and Exhibits (d) Exhibits

<u>Exhibit</u>	<u>Description</u>
----------------	--------------------

<u>No.</u>	<u>Description</u>
------------	--------------------

99.1	Press Release of the Company, dated November 21, 2014
------	---

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Biospecifics Technologies Corp.**

Date: November 21, 2014 By:

/s/ Thomas L. Wegman  
Thomas L. Wegman  
President

**EXHIBIT INDEX**

<b><u>Exhibit</u></b>	<b><u>Description</u></b>
<b><u>No.</u></b>	
99.1	<u>Press Release of the Company, dated November 21, 2014</u>

---